The Botox® Market Is Changing: Daxxify™, Galderma’s Innovations, and What It Means for Patients in London
Neuromodulators are evolving. While Botox® remains the reference standard, long-duration options and ready-to-use formulations are reshaping expectations. Here’s a clear, clinician-led update on where things stand today and how we approach these developments at Santi London.
At a glance
Botox® remains the benchmark
Extensive safety data and predictable results have made onabotulinumtoxinA the market reference for decades.
Daxxify™: longer duration
US-approved for glabellar lines; pivotal studies report many patients maintaining results for ~6 months between treatments.
Galderma’s innovations
Azzalure® (abobotulinumtoxinA) is established; Alluzience® is a ready-to-use liquid formulation. New liquid tox pipelines continue to mature.
What is Daxxify™?
Daxxify™ (daxibotulinumtoxinA-lanm) is a neuromodulator approved in the United States for the temporary improvement of frown lines (glabellar lines). Its key point of difference is a novel peptide-based stabiliser (rather than human serum albumin), with clinical trials showing many patients achieving around six months of effect—meaning fewer treatment visits for suitable candidates.
How it differs from Botox®
- Stabiliser: peptide-based vs human serum albumin in some legacy products.
- Duration: many patients report results lasting ~6 months; individual response varies.
- Price/visit: longer duration can mean fewer annual sessions, but per-treatment pricing may differ; overall cost-effectiveness depends on goals and dosing.
Galderma’s role: Azzalure® and Alluzience® (ready-to-use liquid)
Galderma (with manufacturing partner Ipsen) markets Azzalure® in the UK and EU (abobotulinumtoxinA for aesthetic indications). More recently, Alluzience®—a ready-to-use liquid botulinum toxin type A—has been approved across Europe, streamlining preparation and supporting consistent dosing. Select clinical programmes also evaluate liquid neuromodulators for extended duration and multi-area treatment design.
Why a liquid toxin matters
Eliminating reconstitution can support dosing precision and reduce variability. For clinics, it’s operationally efficient; for patients, it’s about consistency and outcomes—assuming like-for-like technique and indication.
Which neuromodulators are licensed for aesthetic use in the UK?
Currently licensed botulinum toxin type A products for aesthetic procedures in the UK include Botox®, Azzalure®, Alluzience®, Bocouture®, Letybo®, Nuceiva® and others. Availability, indications and brand names can vary; we always follow the Summary of Product Characteristics and MHRA guidance.
Quick comparison (high-level)
| Product | Regulatory status (core aesthetic) | Formulation | Typical duration* | Notable points |
|---|---|---|---|---|
| Botox® (onabotulinumtoxinA) | Licensed in UK for aesthetic indications | Powder (reconstituted) | ~3–4 months | Benchmark safety/efficacy; multiple indications |
| Azzalure® (abobotulinumtoxinA) | Licensed in UK for aesthetic indications | Powder (reconstituted) | ~3–4 months | EU/UK aesthetic brand of Dysport® |
| Alluzience® (abobotulinumtoxinA, liquid) | Licensed in UK/EU (ready-to-use) | Liquid (no reconstitution) | Up to ~6 months in some patients | Operationally efficient; dosing precision |
| Daxxify™ (daxibotulinumtoxinA-lanm) | US-approved; UK availability limited | Powder with peptide stabiliser | ~6 months (varies) | Fewer annual visits for suitable patients |
*Durations are typical ranges reported in clinical studies/real-world use; individual results vary by dose, indication, muscle mass, metabolism and technique.
How Santi London approaches new toxins
Evidence first
We review pivotal trials, post-marketing safety data and real-world outcomes. Longer duration is appealing, but safety, dose-response and predictability remain paramount.
Patient-centred planning
Some patients prefer fewer visits; others value the flexibility of shorter-acting options while they fine-tune dosing or treatment areas across the year.
Regulatory compliance
Products must be appropriately licensed, supplied through legitimate UK channels and administered by qualified prescribers in a clinical setting.
Transparent pricing
We discuss cost-per-visit vs annual plan value so you can choose what best fits your goals and schedule.
Who might consider a longer-duration toxin?
- Busy schedules seeking fewer clinic visits per year.
- Stable, well-mapped treatment plans with predictable dosing.
- Patients who have tolerated neuromodulators well and want to extend intervals.
Not everyone benefits from maximal duration—new starters or those adjusting plans sometimes prefer the flexibility of standard intervals.
Safety and governance
Botulinum toxin is a prescription-only medicine. It should be sourced from UK-licensed suppliers and administered by trained, qualified clinicians under appropriate governance, with aftercare and complication pathways in place. We follow MHRA guidance and actively educate patients on recognising legitimate products and safe settings.
FAQs
Is Daxxify™ available at Santi London?
We continually evaluate emerging options. When UK availability, regulatory status and our clinical due-diligence criteria align, we’ll communicate clearly to patients. In the meantime, we offer established, licensed neuromodulators with strong safety records.
Is Alluzience® “stronger” than Azzalure®?
Alluzience® is a ready-to-use liquid version of abobotulinumtoxinA. Its advantage is operational consistency and dosing precision rather than being “stronger”. Clinical plans are always individualised.
Will longer-lasting toxins cost more?
Per-treatment pricing can be higher, but you may need fewer sessions annually. We review total yearly value, not just single-visit price.
What if I prefer shorter intervals?
That’s a valid choice. Many patients like the flexibility of adjusting dose/areas seasonally. We’ll tailor a plan around your preferences.
How do I know a clinic uses legitimate products?
Ask about UK licensing, prescription pathways, and supply chain. Treatments should be delivered in a clinical setting by qualified prescribers with robust aftercare and complication protocols.
Book a consultation
Curious whether a longer-duration option suits you—or prefer to optimise your current plan? Book a consultation and we’ll map a treatment schedule that fits your goals and diary.
Medical disclaimer: Information is educational and not a substitute for an in-person consultation. Outcomes and durations vary. Prescription-only medicines must be provided by qualified prescribers following UK regulations.